PDF(Pubmed)
Abstract：
BACKGROUND: Ketogenic diets have anti-inflammatory and neuroprotective properties which make these diets an attractive complimentary treatment approach for patients living with multiple sclerosis (MS). The objective of this study was to assess the impact of ketogenic diets on neurofilament light chain (NfL), a biomarker of neuroaxonal injury.
METHODS: Thirty-nine subjects with relapsing MS completed a 6-month ketogenic diet intervention. NfL levels were assayed at both baseline (pre-diet) and 6-months on-diet. In addition, ketogenic diet study participants were compared to a cohort (n = 31) of historical, untreated MS controls.
RESULTS: Baseline (pre-diet) mean NfL was 5.45 pg/ml (95% CI 4.59 - 6.31). After 6 months on ketogenic diet, mean NfL was not significantly changed (5.49 pg/ml; 95% CI 4.82 - 6.19). Compared to untreated MS controls (mean 15.17 pg/ml), NfL levels for the ketogenic diet cohort were relatively low. MS subjects with higher levels of ketosis (as measured by serum beta-hydroxybutyrate) exhibited greater reductions in NfL between baseline and 6-months on ketogenic diet.
CONCLUSIONS: Ketogenic diets do not worsen biomarkers of neurodegeneration in relapsing MS patients, with stable, low levels of NfL observed throughout the diet intervention. Subjects with greater biomarkers of ketosis experienced a higher degree of improvement in serum NfL.
BACKGROUND: NCT03718247 - \"Utilization of the Ketogenic Diet in Patients with Relapsing-Remitting MS\" https://clinicaltrials.gov/ct2/show/NCT03718247.
METHODS: Thirty-nine subjects with relapsing MS completed a 6-month ketogenic diet intervention. NfL levels were assayed at both baseline (pre-diet) and 6-months on-diet. In addition, ketogenic diet study participants were compared to a cohort (n = 31) of historical, untreated MS controls.
RESULTS: Baseline (pre-diet) mean NfL was 5.45 pg/ml (95% CI 4.59 - 6.31). After 6 months on ketogenic diet, mean NfL was not significantly changed (5.49 pg/ml; 95% CI 4.82 - 6.19). Compared to untreated MS controls (mean 15.17 pg/ml), NfL levels for the ketogenic diet cohort were relatively low. MS subjects with higher levels of ketosis (as measured by serum beta-hydroxybutyrate) exhibited greater reductions in NfL between baseline and 6-months on ketogenic diet.
CONCLUSIONS: Ketogenic diets do not worsen biomarkers of neurodegeneration in relapsing MS patients, with stable, low levels of NfL observed throughout the diet intervention. Subjects with greater biomarkers of ketosis experienced a higher degree of improvement in serum NfL.
BACKGROUND: NCT03718247 - \"Utilization of the Ketogenic Diet in Patients with Relapsing-Remitting MS\" https://clinicaltrials.gov/ct2/show/NCT03718247.
摘要：
背景:生酮饮食具有抗炎和神经保护特性,这使得这些饮食对于患有多发性硬化症(MS)的患者而言是有吸引力的补充治疗方法。本研究的目的是评估生酮饮食对神经丝轻链（NfL）的影响，神经轴索损伤的生物标志物。
方法：39例复发性MS患者完成了为期6个月的生酮饮食干预。在基线(饮食前)和6个月饮食时测定NfL水平。此外,生酮饮食研究参与者与一个历史队列(n=31)进行了比较，未处理的MS对照。
结果：基线（饮食前）平均NfL为5.45pg/ml（95％CI4.59-6.31）。生酮饮食6个月后，平均NfL无显著变化(5.49pg/ml;95%CI4.82-6.19)。与未经处理的MS对照（平均15.17pg/ml）相比，生酮饮食队列的NfL水平相对较低。具有较高水平的酮症(如通过血清β-羟基丁酸酯测量的)的MS受试者在基线和生酮饮食的6个月之间表现出更大的NfL降低。
结论：生酮饮食不会使复发性MS患者神经变性的生物标志物恶化，稳定,在整个饮食干预中观察到低水平的NfL。具有更高的酮症生物标志物的受试者在血清NfL中经历了更高程度的改善。
背景：NCT03718247-\"复发MS患者使用生酮饮食\"https://clinicaltrials.gov/ct2/show/NCT03718247。
方法：39例复发性MS患者完成了为期6个月的生酮饮食干预。在基线(饮食前)和6个月饮食时测定NfL水平。此外,生酮饮食研究参与者与一个历史队列(n=31)进行了比较，未处理的MS对照。
结果：基线（饮食前）平均NfL为5.45pg/ml（95％CI4.59-6.31）。生酮饮食6个月后，平均NfL无显著变化(5.49pg/ml;95%CI4.82-6.19)。与未经处理的MS对照（平均15.17pg/ml）相比，生酮饮食队列的NfL水平相对较低。具有较高水平的酮症(如通过血清β-羟基丁酸酯测量的)的MS受试者在基线和生酮饮食的6个月之间表现出更大的NfL降低。
结论：生酮饮食不会使复发性MS患者神经变性的生物标志物恶化，稳定,在整个饮食干预中观察到低水平的NfL。具有更高的酮症生物标志物的受试者在血清NfL中经历了更高程度的改善。
背景：NCT03718247-\"复发MS患者使用生酮饮食\"https://clinicaltrials.gov/ct2/show/NCT03718247。
